- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT00997906
Cisplatin and RT With or Without Gemcitabine, Carboplatin, and Paclitaxel in Treating Patients With Locally Advanced NPC
A Randomised Phase II/III Study of Concurrent Cisplatin-Radiotherapy With or Without Induction Chemotherapy Using Gemcitabine, Carboplatin and Paclitaxel in Locally Advanced Nasopharyngeal Cancer
RATIONALE: Drugs used in chemotherapy, such as cisplatin, gemcitabine hydrochloride, carboplatin, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving chemotherapy together with radiation therapy my kill more tumor cells. It is not yet known whether giving cisplatin together with radiation therapy is more effective with or without gemcitabine hydrochloride, carboplatin, and paclitaxel in treating patients with nasopharyngeal cancer.
PURPOSE: This randomized phase II/III trial is studying how well giving cisplatin together with radiation therapy works compared with giving cisplatin and radiation therapy together with gemcitabine hydrochloride, carboplatin, and paclitaxel in treating patients with locally advanced nasopharyngeal cancer.
Studieoversigt
Status
Betingelser
Detaljeret beskrivelse
OBJECTIVES:
Primary
- To compare the 5-year overall survival of patients with locally advanced nasopharyngeal cancer treated with concurrent cisplatin and radiotherapy with vs without induction chemotherapy comprising gemcitabine hydrochloride, carboplatin, and paclitaxel.
Secondary
- To assess and compare the disease-free survival, distant metastases rate, toxicities, and quality of life of patients treated with these regimens.
OUTLINE: Patients are stratified by N-stage (N0-1 vs N2-3) and are randomized to 1 of 2 treatment arms.
- Arm I: Patients receive cisplatin IV over 2 hours once weekly on weeks 1-8 and undergo intensity-modulated radiotherapy once daily, 5 days a week, on weeks 1-7 (6½ weeks for a total of 33 fractions).
- Arm II: Patients receive induction chemotherapy comprising gemcitabine hydrochloride IV over 30 minutes, carboplatin IV over 1 hour, and paclitaxel IV over 1 hour on days 1 and 8. Treatment repeats every 21 days for 3 courses. Beginning at least 3 weeks after the last dose of induction chemotherapy, patients receive cisplatin and undergo radiotherapy as in arm I.
Quality of life is assessed periodically.
After completion of study treatment, patients are followed every 2 months for 1 year, every 4 months for 1 year, every 6 months for 2 years, and then annually thereafter.
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 2
- Fase 3
Kontakter og lokationer
Studiesteder
-
-
-
Singapore, Singapore, 169610
- National Cancer Centre - Singapore
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion criteria:
Patients are eligible for inclusion if all of the following criteria are fulfilled:
- Have given written informed consent, with the understanding that consent may be withdrawn at any time without prejudice.
- Loco-regional advanced NPC UICC (1997) Stages T3 - 4 any N, or any Stage T, N2 - 3.
- A histological diagnosis of WHO Type II or III NPC must have been established at some time and the investigator must review and confirm the diagnosis prior to randomization.
- No evidence of distant metastases in staging work up (including lung, liver and bone imaging).
- Cross sectional imaging of the primary and neck disease (MRI preferred)
- Evaluable disease must be present.
- Performance status of ECOG grade 0 or 1 (see Appendix I).
- No prior tumour therapy
Adequate bone marrow, renal and hepatic function:
Bone marrow : WBC > 3000 / mm3 (ANC > 1500 / mm3 ),
- Platelets > 100 000 / mm3,
- Hb > 10 gm/dl Renal : serum creatinine within institutional normal range (or) lower than the lower limit of institutional normal range
- calculated creatinine clearance > 50 ml / min Hepatic : enzymes (SAP, SGOT) < 2x normal
- bilirubin < 24 µmol / l.
- At least 18 years of age, of either sex.
Exclusion criteria:
Patients are to be excluded from the study if any of the following criteria is fulfilled:
- Uncontrolled hypercalcaemia: calcium ≥ 2.7 mmol/L (10.8 mg/dL).
- Second primary malignancy (except in situ carcinoma of the cervix or adequately treated basal cell carcinoma of the skin).
- Other serious concomitant systemic disorders incompatible with the study (at the discretion of the investigator).
- Have serious active infection.
- Hepatitis B carrier
- Prior treatment including chemotherapy or radiotherapy.
- Pregnant or lactating female subjects and subjects with reproductive potential not implementing adequate contraceptive measures.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Eksperimentel: Arm I
Patients receive cisplatin IV over 2 hours once weekly on weeks 1-8 and undergo intensity-modulated radiotherapy once daily, 5 days a week, on weeks 1-7 (6½ weeks for a total of 33 fractions).
|
Givet IV
Given once daily 5 days a week for 6½ weeks.
|
Eksperimentel: Arm II
Patients receive induction chemotherapy comprising gemcitabine hydrochloride IV over 30 minutes, carboplatin IV over 1 hour, and paclitaxel IV over 1 hour on days 1 and 8. Treatment repeats every 21 days for 3 courses.
Beginning at least 3 weeks after the last dose of induction chemotherapy, patients receive cisplatin and undergo radiotherapy as in arm I.
|
Givet IV
Givet IV
Givet IV
Given once daily 5 days a week for 6½ weeks.
Given IV
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Tidsramme |
---|---|
Samlet overlevelse ved 5 år
Tidsramme: 5 år
|
5 år
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
---|---|
Sygdomsfri overlevelse
Tidsramme: 10 år
|
10 år
|
Metastases-free survival
Tidsramme: 10 years
|
10 years
|
Tumor recurrence
Tidsramme: 10 years
|
10 years
|
Toxicity according to the Common Toxicity Criteria
Tidsramme: 10 years
|
10 years
|
Quality of life as measured by the EORTC QLQ-C30
Tidsramme: 5 years
|
5 years
|
Samarbejdspartnere og efterforskere
Efterforskere
- Ledende efterforsker: Terence Tan, FRCR, National Cancer Centre, Singapore
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Forventet)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Neoplasmer
- Neoplasmer efter sted
- Neoplasmer i hoved og hals
- Lægemidlers fysiologiske virkninger
- Molekylære mekanismer for farmakologisk virkning
- Anti-infektionsmidler
- Antivirale midler
- Enzymhæmmere
- Antimetabolitter, Antineoplastisk
- Antimetabolitter
- Antineoplastiske midler
- Immunsuppressive midler
- Immunologiske faktorer
- Tubulin modulatorer
- Antimitotiske midler
- Mitose modulatorer
- Antineoplastiske midler, fytogene
- Gemcitabin
- Carboplatin
- Paclitaxel
Andre undersøgelses-id-numre
- CDR0000657121
- SINGAPORE-NCC0901 (Anden identifikator: National Cancer Centre Singapore)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med gemcitabin hydrochlorid
-
Beth ChristianAfsluttetTilbagevendende voksen Hodgkin-lymfom | Voksen lymfocytdepletion Hodgkin lymfom | Voksen lymfocytdominerende Hodgkin-lymfom | Hodgkin-lymfom med blandet cellularitet hos voksne | Nodulær sklerose hos voksne Hodgkin-lymfom | Voksen nodulær lymfocytdominerende Hodgkin-lymfomForenede Stater
-
OSI PharmaceuticalsNational Cancer Institute (NCI)AfsluttetKræft i bugspytkirtlen | Uspecificeret fast tumor hos voksne, protokolspecifikForenede Stater
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Afsluttet
-
NCIC Clinical Trials GroupAfsluttetKræft i bugspytkirtlenForenede Stater, Canada, Australien, Singapore, Belgien, Det Forenede Kongerige, Israel, New Zealand, Kina, Tyskland, Brasilien, Polen, Italien, Argentina, Rumænien, Grækenland, Chile, Hong Kong, Mexico
-
NCIC Clinical Trials GroupAfsluttet
-
National Cancer Institute (NCI)AfsluttetAdenocarcinom i bugspytkirtlen | Tilbagevendende kræft i bugspytkirtlen | Stadie III Bugspytkirtelkræft | Fase II Kræft i bugspytkirtlenForenede Stater
-
UNC Lineberger Comprehensive Cancer CenterNational Cancer Institute (NCI)AfsluttetLungekræftForenede Stater
-
Institute of Liver and Biliary Sciences, IndiaRekruttering
-
Tripler Army Medical CenterTrukket tilbageSvangerskabsdiabetesForenede Stater
-
Centre Antoine LacassagneAfsluttetKræft i bugspytkirtlenFrankrig